Skip to main content
All lobbying firms

AEGIS LLC

Registrant on federal lobbying filings · filed 2025 to 2026

$770,000 Income reported
2 Clients represented
14 Filings counted
0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. Everything on this page is grouped by the registrant's LDA id (401108688), not by name.

 Clients 2
 Lobbyists named 1
  • ANNE ELIZABETH ESPOSITO 14 filings · through 2026 Health Policy Coordinator, Energy and Commerce Committee; Health Policy Advisor, Health Subcommittee (Chairman Bilirakis)

A lobbyist who previously held a covered government position must disclose it. We flag the ones whose name resolves to a member of Congress and link the ones still in our roster. The revolving door collects them across every firm.

 Reported by year 2 years
  • 2026 $330,000 6 filings
  • 2025 $440,000 8 filings
 Issues lobbied 2

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 3
  • HOUSE OF REPRESENTATIVES 14
  • SENATE 14
  • Natl Highway Traffic Safety Administration (NHTSA) 3
 Recent filings 14 total
Q3 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 17, 2026
View → Q3 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 17, 2026
View → Q2 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 2, 2026
View → Q2 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 2, 2026
View → Q1 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 7, 2026
View → Q1 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 7, 2026
View → Q4 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $60,000 income · posted Jan 12, 2026
View → Q4 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 12, 2026
View → Q3 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 10, 2025
View → Q3 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 10, 2025
View → Q2 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 18, 2025
View → Q2 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 18, 2025
View → Q1 report
TRIS PHARMA, INC. AND ITS WHOLLY OWNED SUBSIDIARY ADNEURIS THERAPEUTICS FKA TRIS
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 4, 2025
View → Q1 report
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $60,000 income · posted Apr 4, 2025
View →

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem